Compare Iron Mountain Inc (IRM) vs Johnson & Johnson (JNJ) Price & Performance

Iron Mountain (IRM) trades at $124.38, up 0.45% for the day, with a bullish technical signal and strong recent earnings beats. The stock has rallied 30.2% over three months, supported by data center growth and recurring storage revenue. However, the company faces high debt levels, with a debt-to-asset ratio of 74.39% in 2024, and a P/E ratio of 134.59 suggests elevated valuation. Analyst consensus is bullish with a $138.67 price target, though the RSI_6 at 84.86 indicates potential overbought conditions near-term.

Outlook remains positive due to consistent earnings outperformance and data center expansion, but risks include significant leverage and declining paper storage demand. The stock offers a dividend yield with a recent $0.86 payment, yet investors should weigh high valuation multiples against growth prospects in a competitive information services sector.

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.